Patient demographics
| Demographics . | N = 43 . |
|---|---|
| Median age, y (range) | 60 (39-77) |
| Sex, n (%) | |
| Female | 17 (40) |
| Male | 26 (60) |
| Binet stage, n (%) | |
| A | 1 (2) |
| B | 24 (36) |
| C | 18 (42) |
| Median time from diagnosis to FCC, mo (range) | 69 (10-276) |
| Median time from last treatment to FCC, mo (range) | 14 (1-90) |
| Disease status, n (%) | |
| Relapsed | 32 (74) |
| Refractory | 11 (26) |
| No. of prior treatments, n (%) | |
| 1 | 10 (23) |
| 2 | 20 (46) |
| ≥ 3 | 13 (31) |
| Prior fludarabine | 40 (93) |
| Prior alkylating agent | 38 (88) |
| Prior monoclonal antibody | 16 (37) |
| Fludarabine refractory* | 6 (15) |
| IgVH status,* n (%) | |
| Mutated | 11 (32) |
| Unmutated | 23 (68) |
| ZAP-70,* n (%) | |
| Negative | 16 (48) |
| Positive | 17 (52) |
| FISH,* n (%) | |
| Normal or 13q deletion | 15 (38) |
| Trisomy 12 | 6 (15) |
| 11q deletion | 7 (18) |
| 17p deletion | 11 (28) |
| Demographics . | N = 43 . |
|---|---|
| Median age, y (range) | 60 (39-77) |
| Sex, n (%) | |
| Female | 17 (40) |
| Male | 26 (60) |
| Binet stage, n (%) | |
| A | 1 (2) |
| B | 24 (36) |
| C | 18 (42) |
| Median time from diagnosis to FCC, mo (range) | 69 (10-276) |
| Median time from last treatment to FCC, mo (range) | 14 (1-90) |
| Disease status, n (%) | |
| Relapsed | 32 (74) |
| Refractory | 11 (26) |
| No. of prior treatments, n (%) | |
| 1 | 10 (23) |
| 2 | 20 (46) |
| ≥ 3 | 13 (31) |
| Prior fludarabine | 40 (93) |
| Prior alkylating agent | 38 (88) |
| Prior monoclonal antibody | 16 (37) |
| Fludarabine refractory* | 6 (15) |
| IgVH status,* n (%) | |
| Mutated | 11 (32) |
| Unmutated | 23 (68) |
| ZAP-70,* n (%) | |
| Negative | 16 (48) |
| Positive | 17 (52) |
| FISH,* n (%) | |
| Normal or 13q deletion | 15 (38) |
| Trisomy 12 | 6 (15) |
| 11q deletion | 7 (18) |
| 17p deletion | 11 (28) |
FCC indicates fludarabine, cyclophosphamide, alemtuzumab.
Data not available for all patients.